NEKTAR THERAPEUTICS (NKTR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 10M 20M 30M Q3 '21: 24.9M Q4 '21: 25M Q1 '22: 24.8M Q2 '22: 21.6M Q3 '22: 23.6M Q4 '22: 22M Q1 '23: 21.6M Q2 '23: 20.5M Q3 '23: 24.1M Q4 '23: 23.9M Q1 '24: 21.6M Q2 '24: 23.5M Q3 '24: 24.1M Q4 '24: 29.2M Q1 '25: 10.5M Q2 '25: 11.2M Q3 '25: 11.8M Q4 '25: 21.8M Q1 '26: 10.9M Q2 '26: 10.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

-4M -2M 0 2M 4M 6M Q1 '10: -2.5M Q2 '10: 4.5M Q3 '10: -760K Q4 '10: 463K Q1 '11: -789K Q2 '11: 501K Q3 '11: 2.6M Q4 '11: 623K Q1 '10 Q2 '10 Q3 '10 Q4 '10 Q1 '11 Q2 '11 Q3 '11 Q4 '11

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: -113.6M Q4 '21: -112.9M Q1 '22: -116.6M Q2 '22: -152.8M Q3 '22: -54.3M Q4 '22: -52.5M Q1 '23: -134.7M Q2 '23: -50.6M Q3 '23: -44.9M Q4 '23: -33.5M Q1 '24: -35.4M Q2 '24: -49.8M Q3 '24: -34.3M Q4 '24: 14.3M Q1 '25: -44.5M Q2 '25: -36.2M Q3 '25: -31.7M Q4 '25: -27.7M Q1 '26: -39.1M Q2 '26: -42.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: -129.7M Q4 '21: -145.6M Q1 '22: -90.4M Q2 '22: -159.1M Q3 '22: -59M Q4 '22: -59.7M Q1 '23: -137M Q2 '23: -51.1M Q3 '23: -45.8M Q4 '23: -42.1M Q1 '24: -36.8M Q2 '24: -52.4M Q3 '24: -37.1M Q4 '24: 7.3M Q1 '25: -50.9M Q2 '25: -41.6M Q3 '25: -35.5M Q4 '25: -36.1M Q1 '26: -44.9M Q2 '26: -40.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 5M 10M 15M Q1 '21: 5.8M Q2 '21: 7.7M Q3 '21: 5.3M Q4 '21: 6.2M Q1 '22: 5.3M Q2 '22: 5.1M Q3 '22: 5M Q4 '22: 6.2M Q1 '23: 7.1M Q2 '23: 7M Q3 '23: 12.4M Q4 '23: 7.3M Q1 '24: 8.5M Q2 '24: 9.7M Q3 '24: 4.4M Q4 '24: 8M Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: -101.1M Q4 '21: -151.5M Q1 '22: -88.4M Q2 '22: -75M Q3 '22: -82.9M Q4 '22: -57.7M Q1 '23: -51.9M Q2 '23: -51.5M Q3 '23: -42.1M Q4 '23: -47M Q1 '24: -47.9M Q2 '24: -37.7M Q3 '24: -43.9M Q4 '24: -46.2M Q1 '25: -49.1M Q2 '25: -45.7M Q3 '25: -48.8M Q4 '25: -65M Q1 '26: -44.3M Q2 '26: -75.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: -104.1M Q4 '21: -157.4M Q1 '22: -92.6M Q2 '22: -75.8M Q3 '22: -83.1M Q4 '22: -58.2M Q1 '23: -52.3M Q2 '23: -51.7M Q3 '23: -42.2M Q4 '23: -47.3M Q1 '24: -48M Q2 '24: -37.9M Q3 '24: -44.6M Q4 '24: -46.6M Q1 '25: -49.1M Q2 '25: -45.8M Q3 '25: -48.9M Q4 '25: -65M Q1 '26: -44.3M Q2 '26: -75.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '19: 175.4M Q2 '20: 178.3M Q3 '20: 179.1M Q1 '21: 181.4M Q2 '21: 182.7M Q3 '21: 184.1M Q1 '22: 185.8M Q2 '22: 186.8M Q3 '22: 187.6M Q1 '23: 188.9M Q2 '23: 189.7M Q3 '23: 190.4M Q1 '24: 194.7M Q2 '24: 13.9M Q3 '24: 13.9M Q1 '25: 14.1M Q2 '25: 14.1M Q3 '25: 18.9M Q1 '26: 24.7M Q2 '26: 33.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-900.00 -600.00 -300.00 0.00 300.00 600.00 900.00 Q3 '21: -2.72 Q4 '21: -792.07 Q1 '22: -791.88 Q2 '22: -792.04 Q3 '22: -791.65 Q4 '22: -1.97 Q1 '23: -2.21 Q2 '23: -1.63 Q3 '23: -1.56 Q4 '23: -1.46 Q1 '24: -0.92 Q2 '24: -4.41 Q3 '24: -6.83 Q4 '24: -8.68 Q1 '25: -12.11 Q2 '25: -11.30 Q3 '25: -10.51 Q4 '25: -10.03 Q1 '26: -8.23 Q2 '26: -6.51 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.